Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Deferred Taxes (2020 - 2024)

Maravai Lifesciences Holdings (MRVI) has 5 years of Deferred Taxes data on record, last reported at $11000.0 in Q4 2024.

  • For Q4 2024, Deferred Taxes fell 100.0% year-over-year to $11000.0; the TTM value through Dec 2024 reached $11000.0, down 100.0%, while the annual FY2025 figure was -$20000.0, 281.82% down from the prior year.
  • Deferred Taxes reached $11000.0 in Q4 2024 per MRVI's latest filing, down from $764.8 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $764.8 million in Q4 2023 and bottomed at -$5.5 million in Q3 2023.
  • Average Deferred Taxes over 5 years is $52.4 million, with a median of $6.7 million recorded in 2021.
  • Peak YoY movement for Deferred Taxes: surged 1122800.0% in 2021, then plummeted 159.91% in 2023.
  • A 5-year view of Deferred Taxes shows it stood at -$4.2 million in 2020, then surged by 516.95% to $17.5 million in 2021, then crashed by 59.86% to $7.0 million in 2022, then soared by 10807.86% to $764.8 million in 2023, then plummeted by 100.0% to $11000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were $11000.0 in Q4 2024, $764.8 million in Q4 2023, and -$5.5 million in Q3 2023.